Upadacitinib (RINVOQ)

Janus kinase (JAK) inhibitor (selective immunosuppressant)

Upadacitinib (RINVOQ)

Forms and strengths
Form: TabletStrength: 15 mg, 30 mg, 45 mg
Print

Indication

  • Upadacitinib (RINVOQ) is used for moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate, as monotherapy or combined with methotrexate or other nonbiologic DMARDs.
  • It is used for active psoriatic arthritis in adults who have had an inadequate response or intolerance to methotrexate or other DMARDs.
  • It is used for active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults who have had an inadequate response to a biologic DMARD or when those therapies are inadvisable.
  • It is used for giant cell arteritis in adults, combined with a tapering course of corticosteroids or as monotherapy after corticosteroids are stopped.
  • It is used for refractory moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older weighing at least 40 kg who are not adequately controlled with, or cannot use, a systemic treatment.
  • It is used for moderately to severely active ulcerative colitis and Crohn's disease in adults who have had an inadequate response, loss of response, or intolerance to conventional or biologic therapy.
  • Upadacitinib should not be combined with other JAK inhibitors, immunomodulating biologics, or potent immunosuppressants such as azathioprine, 6-mercaptopurine, or cyclosporine.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.